Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GLP-1Ra in Stage 2 and Early Stage 3 T1DM with Teplizumab
NCT06338553Phase 1Recruiting
- Sponsor
- Vanderbilt University Medical Center
- Start
- Jun 2024
- Primary completion
- Mar 2027
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of semaglutide in type 1 diabetes mellitus (T1D) (4 arms), sponsored by Vanderbilt University Medical Center. Primary endpoints: Postprandial glycemia during Mixed Meal Tolerance Test (MMTT), Disposition index (DI) and 2 more. Started Jun 2024; status: recruiting.
02
Drugs
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT06338553.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06338553.